Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 12 studies | 25% ± 11% | |
astrocyte | 10 studies | 32% ± 14% | |
oligodendrocyte | 9 studies | 29% ± 10% | |
GABAergic neuron | 8 studies | 34% ± 18% | |
oligodendrocyte precursor cell | 7 studies | 29% ± 13% | |
microglial cell | 6 studies | 23% ± 6% | |
fibroblast | 6 studies | 22% ± 6% | |
smooth muscle cell | 6 studies | 19% ± 3% | |
epithelial cell | 5 studies | 30% ± 10% | |
adipocyte | 5 studies | 20% ± 3% | |
ciliated cell | 5 studies | 27% ± 9% | |
endothelial cell of lymphatic vessel | 5 studies | 21% ± 3% | |
glutamatergic neuron | 5 studies | 47% ± 21% | |
macrophage | 5 studies | 29% ± 4% | |
interneuron | 5 studies | 39% ± 21% | |
natural killer cell | 4 studies | 19% ± 2% | |
lymphocyte | 4 studies | 21% ± 4% | |
myeloid cell | 4 studies | 21% ± 5% | |
T cell | 4 studies | 18% ± 1% | |
club cell | 4 studies | 19% ± 5% | |
pericyte | 4 studies | 21% ± 3% | |
type I pneumocyte | 4 studies | 22% ± 7% | |
type II pneumocyte | 4 studies | 24% ± 6% | |
neuron | 4 studies | 35% ± 15% | |
squamous epithelial cell | 3 studies | 36% ± 14% | |
mononuclear phagocyte | 3 studies | 17% ± 2% | |
monocyte | 3 studies | 23% ± 3% | |
basal cell | 3 studies | 25% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1103.99 | 1444 / 1445 | 100% | 15.24 | 183 / 183 |
lung | 100% | 1404.55 | 578 / 578 | 96% | 8.38 | 1113 / 1155 |
stomach | 99% | 656.02 | 357 / 359 | 95% | 8.00 | 273 / 286 |
breast | 100% | 1027.50 | 459 / 459 | 93% | 10.98 | 1038 / 1118 |
intestine | 100% | 872.51 | 966 / 966 | 92% | 5.90 | 485 / 527 |
ovary | 100% | 1043.96 | 180 / 180 | 89% | 6.60 | 384 / 430 |
pancreas | 99% | 474.72 | 326 / 328 | 89% | 5.39 | 158 / 178 |
skin | 100% | 1169.77 | 1808 / 1809 | 88% | 6.70 | 416 / 472 |
prostate | 100% | 820.85 | 245 / 245 | 85% | 6.17 | 425 / 502 |
kidney | 100% | 515.66 | 89 / 89 | 82% | 6.34 | 737 / 901 |
bladder | 100% | 1026.71 | 21 / 21 | 81% | 5.18 | 406 / 504 |
thymus | 100% | 926.24 | 650 / 653 | 81% | 5.15 | 489 / 605 |
uterus | 100% | 1257.13 | 170 / 170 | 79% | 5.44 | 363 / 459 |
brain | 89% | 349.21 | 2347 / 2642 | 90% | 5.39 | 633 / 705 |
adrenal gland | 98% | 480.02 | 253 / 258 | 47% | 1.76 | 108 / 230 |
liver | 95% | 321.72 | 215 / 226 | 47% | 2.05 | 189 / 406 |
adipose | 100% | 1002.22 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 660.35 | 241 / 241 | 0% | 0 | 0 / 0 |
muscle | 100% | 736.54 | 802 / 803 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 956.42 | 1333 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 93% | 826.73 | 865 / 929 | 0% | 0 | 0 / 0 |
heart | 92% | 438.13 | 790 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 76% | 6.79 | 34 / 45 |
eye | 0% | 0 | 0 / 0 | 68% | 2.87 | 54 / 80 |
lymph node | 0% | 0 | 0 / 0 | 55% | 3.64 | 16 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0000724 | Biological process | double-strand break repair via homologous recombination |
GO_0006974 | Biological process | DNA damage response |
GO_0016567 | Biological process | protein ubiquitination |
GO_2000780 | Biological process | negative regulation of double-strand break repair |
GO_0006302 | Biological process | double-strand break repair |
GO_0005730 | Cellular component | nucleolus |
GO_0016604 | Cellular component | nuclear body |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0035861 | Cellular component | site of double-strand break |
GO_0005634 | Cellular component | nucleus |
GO_0031491 | Molecular function | nucleosome binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0061649 | Molecular function | ubiquitin-modified histone reader activity |
GO_0070530 | Molecular function | K63-linked polyubiquitin modification-dependent protein binding |
GO_0005515 | Molecular function | protein binding |
GO_0046872 | Molecular function | metal ion binding |
Gene name | RNF169 |
Protein name | RING-type E3 ubiquitin transferase (EC 2.3.2.27) E3 ubiquitin-protein ligase RNF169 (EC 2.3.2.27) (RING finger protein 169) (RING-type E3 ubiquitin transferase RNF169) |
Synonyms | KIAA1991 |
Description | FUNCTION: Probable E3 ubiquitin-protein ligase that acts as a regulator of double-strand breaks (DSBs) repair following DNA damage. Functions in a non-canonical fashion to harness RNF168-mediated protein recruitment to DSB-containing chromatin, thereby contributing to regulation of DSB repair pathway utilization . Once recruited to DSB repair sites by recognizing and binding ubiquitin catalyzed by RNF168, competes with TP53BP1 and BRCA1 for association with RNF168-modified chromatin, thereby favouring homologous recombination repair (HRR) and single-strand annealing (SSA) instead of non-homologous end joining (NHEJ) mediated by TP53BP1 . E3 ubiquitin-protein ligase activity is not required for regulation of DSBs repair. . |
Accessions | ENST00000299563.5 Q8NCN4 ENST00000527301.1 H0YEQ1 |